ClinicalTrials.gg
CompletedNCT03392467Updated Jan 24, 2025

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

A Phase 2 interventional study of PNEUMOSTEM and Placebo in Severe Bronchopulmonary Dysplasia, sponsored by Medipost Co Ltd.. Completed at 2 sites in Korea, Republic of. Open to participants aged Up to 13 Days. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Medipost Co Ltd. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
Up to 13 Days
Sex
All
01

Study summary

This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.

Read the detailed description

Bronchopulmonary dysplasia (BPD) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. PNEUMOSTEM is intended to prevent and treat BPD by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects.

02

Conditions studied

  • Severe Bronchopulmonary Dysplasia
03

In context

Bronchopulmonary Dysplasia

362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.

This study's enrollment of 60 is close to the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Medipost Co Ltd. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 13 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

at screening and randomization

  1. 23 weeks to \< 25 weeks of gestational age
  2. 500g to 1,250g body weight at birth
  3. premature infant within postnatal 13 days of age
  4. use ventilator with ventilation rate >12 breaths/min or oxygen supply > 25%, or use high frequency ventilator (HFV)

at IP administration

  1. premature infant within postnatal 5 to 14 days of age
  2. No improvement in ventilator setting 24 hours prior to administration of IP

Exclusion criteria

Exclusion Criteria:

  1. subject with cyanotic congenital heart disease or non-cyanotic congenital heart disease that can cause heart failure
  2. subject with pulmonary hypoplasia, congenital diaphragmatic hernia, or serious lung malformation such as congenital cystic lung disease
  3. subject with chromosome disorder with serious malformation (i.e. Edward syndrome, patau syndrome, Down syndrome, etc.), severe congenital malformation (i.e. hydrocephalus, encephalocele, etc.), or severe congenital infection (i.e., herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.)
  4. subject with serious sepsis as active infection or shock due to sepsis
  5. subject with grade 3 or 4 of bilateral intraventricular hemorrhage
  6. at screening, subject with active pulmonary hemorrhage or active air leak syndrome
  7. subject who underwent/will undergo surgery within 72 hours before/after product (IP) administration
  8. subject who is expected to be treated with surfactant within 24 hours prior to IP administration
  9. subject who is expected to be allergic to gentamicin (Birth mother's allergy for gentamicin will be confirmed).
  10. subject who have previously participated in other clinical trials
  11. subject who is considered ineligible by investigator due to other medical reasons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    PNEUMOSTEM

    human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)

    Biological: PNEUMOSTEM

  • Placebo comparator
    Placebo

    normal saline

    Other: Placebo

Interventions

  • BiologicalPNEUMOSTEM

    human umbilical cord blood-derived mesenchymal stem cells

  • OtherPlacebo

    normal saline

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who have severe BPD or are dead

    Percentage of subjects who have severe BPD or are dead

    Time frame: 36 weeks postmenstrual age (PMA)

Secondary outcomes

  1. Percentage of subjects who have moderate/severe BPD or are dead

    Percentage of subjects who have moderate/severe BPD or are dead

    Time frame: 36 weeks PMA

  2. Percentage of subjects by severity of BPD

    Percentage of subjects by severity of BPD

    Time frame: prenatal 28 days/36 weeks PMA

  3. Percentage of subjects in death due to lung disease

    Percentage of subjects in death due to lung disease

    Time frame: prenatal 28 days/36 weeks PMA and study end timepoint

  4. intubation duration

    intubation duration

    Time frame: up to 24 weeks

  5. ventilation duration

    ventilation duration

    Time frame: up to 24 weeks

  6. continuous positive airway pressure (CPAP) treatment duration

    continuous positive airway pressure (CPAP) treatment duration

    Time frame: up to 24 weeks

  7. treatment duration with supplemental oxygen

    treatment duration with supplemental oxygen

    Time frame: up to 24 weeks

  8. % of subjects treated with steroid for weaning ventilator

    % of subjects treated with steroid for weaning ventilator

    Time frame: up to 24 weeks

  9. Retinopathy of prematurity (ROP) with stage III or higher

    number of subjects with ROP with stage III or higher

    Time frame: up to 24 weeks

  10. number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy

    number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy

    Time frame: up to 24 weeks

  11. z-score

    percentile for body weight, height, and head circumference

    Time frame: up to 24 weeks (visit 10)

  12. days in hospitalization

    days in hospitalization

    Time frame: up to 24 weeks

  13. changes in tracheal suction fluid examination

    changes in tracheal suction fluid examination

    Time frame: from screening to 7 days after IP administration (visit 5)

07

Study locations

2 sites
  • Asan medical Center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Ahn SY, Chang YS, Lee MH, Sung SI, Lee BS, Kim KS, Kim AR, Park WS. Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial. Stem Cells Transl Med. 2021 Aug;10(8):1129-1137. doi: 10.1002/sctm.20-0330. Epub 2021 Apr 20. PubMed 33876883 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jan 2024, 64 months.

Of 19 phase 2 interventional studies under Bronchopulmonary Dysplasia, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 69. This study's 64 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Jan 8, 2018
StartActual
Aug 13, 2018
Primary completionActual
Jan 9, 2024
CompletionActual
Oct 18, 2024
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392467
Lead sponsor
Medipost Co Ltd.
Responsible party
Sponsor
First posted
Jan 8, 2018
Start date
Aug 13, 2018
Primary completion
Jan 9, 2024
Completion
Oct 18, 2024
Last update
Jan 24, 2025

Study contacts

Wonsoon Park
principal investigator · Samsung Medical Center
Airhan Kim
principal investigator · Asan Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion